Mylan N.V. (NASDAQ:MYL) is joined at the hip with Teva. Shares are down 4% premarket on robust volume, matching Teva's decline. Q2 earnings are on tap for Wednesday, August 9 before the open.
Previously: Teva's travails bearish for Mylan - RBC (Aug. 4)
Subscribe for full text news in your inbox